Nurix Therapeutics, Inc.

NASDAQ:NRIX

19.83 (USD) • At close December 20, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 12.58812.09216.58515.15918.46730.67612.6856.78310.79111.4329.6217.39610.2527.0915.0116.6894.0854.1822.8641.86210.589.4399.234
Cost of Revenue 4.1464.0913.8883.7573.3843.3333.183.0372.8862.6322.2530.75730.90625.99423.00320.44518.93914.14212.96712.82411.00810.75910.434
Gross Profit 8.4428.00112.69711.40215.08327.3439.5053.7467.9058.87.3686.639-20.654-18.903-17.992-13.756-14.854-9.96-10.103-10.962-0.428-1.32-1.2
Gross Profit Ratio 0.6710.6620.7660.7520.8170.8910.7490.5520.7330.770.7660.898-2.015-2.666-3.591-2.057-3.636-2.382-3.528-5.887-0.04-0.14-0.13
Reseach & Development Expenses 55.48146.59247.9647.77947.85645.76345.81646.10647.76147.49343.13736.53130.90625.99423.00320.44518.93914.14212.96712.82411.00810.75910.434
General & Administrative Expenses 11.71811.7111.79910.7810.62311.6789.8219.3679.7489.6549.2288.8188.3437.5116.536.2524.3383.272.452.6022.1841.871.67
Selling & Marketing Expenses 0-1.761-1.843-1.8230000000000000000000
SG&A 11.7189.9499.9568.95710.62311.6789.8219.3679.7489.6549.2288.8188.3437.5116.536.2524.3383.272.452.6022.1841.871.67
Other Expenses 00000000000000000000000
Operating Expenses 67.19956.54157.91656.73658.47957.44155.63755.47357.50957.14752.36545.34939.24933.50529.53326.69723.27717.41215.41715.42613.1921.871.67
Operating Income -54.611-48.54-45.219-45.334-40.012-26.765-42.952-48.69-46.718-45.715-42.322-37.953-28.997-26.414-24.522-20.008-19.192-13.23-12.553-13.564-2.612-3.19-2.87
Operating Income Ratio -4.338-4.014-2.726-2.991-2.167-0.873-3.386-7.178-4.329-3.999-4.399-5.132-2.828-3.725-4.894-2.991-4.698-3.164-4.383-7.285-0.247-0.338-0.311
Total Other Income Expenses Net 5.7374.0843.7913.3783.032.4882.2191.9731.0090.3140.2110.2950.0390.1710.3180.1350.6750.2230.1730.2550.1950.1320.194
Income Before Tax -48.874-44.456-41.428-41.956-36.982-24.277-40.733-46.717-45.709-45.401-42.533-37.658-28.958-26.243-24.204-19.873-18.517-13.007-12.38-13.309-2.417-3.058-2.676
Income Before Tax Ratio -3.883-3.676-2.498-2.768-2.003-0.791-3.211-6.887-4.236-3.971-4.421-5.092-2.825-3.701-4.83-2.971-4.533-3.11-4.323-7.148-0.228-0.324-0.29
Income Tax Expense 0.0820.090.097.8873.424-2.488-5.399-5.01-1.009-0.314-0.2110.044-0.1230.1390.0710.041-0.675-20.5870.0110.210.010.010.009
Net Income -48.956-44.546-41.518-41.956-36.982-21.789-35.334-41.707-44.7-45.087-42.322-37.702-28.835-26.382-24.275-19.914-18.5177.58-12.391-13.519-2.427-3.068-2.685
Net Income Ratio -3.889-3.684-2.503-2.768-2.003-0.71-2.785-6.149-4.142-3.944-4.399-5.098-2.813-3.72-4.844-2.977-4.5331.813-4.326-7.26-0.229-0.325-0.291
EPS -0.67-0.71-0.76-0.77-0.68-0.4-0.65-0.77-0.88-1-0.95-0.85-0.65-0.6-0.63-0.51-1.090.22-0.6-0.65-0.12-0.94-0.85
EPS Diluted -0.67-0.71-0.76-0.77-0.68-0.4-0.65-0.77-0.88-1-0.95-0.85-0.65-0.6-0.63-0.51-1.090.22-0.6-0.65-0.12-0.94-0.85
EBITDA -50.465-44.449-41.331-41.577-36.628-23.432-39.772-45.653-42.823-42.769-40.491-37.196-28.252-25.643-23.879-19.364-18.642-12.735-12.062-13.015-2.056-2.587-2.224
EBITDA Ratio -4.009-3.676-2.492-2.743-1.983-0.764-3.386-7.178-4.062-3.769-4.443-5.132-2.756-3.725-4.894-2.991-4.564-3.045-4.212-6.99-0.194-0.274-0.241